242.60

0.70% -1.71

After Hours: 240.00 -2.60 -1.07%

Axsome Therapeutics Inc (AXSM)

Overview News Price History Option Chain Financials Why AXSM Down? Discussions Forecast

Axsome Therapeutics Inc stock is traded at $242.60, with a volume of 842.12K. It is down -0.70% in the last 24 hours and up +4.42% over the past month. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Previous Close:

$244.31

Open:

$245.4

24h Volume:

842.12K

Relative Volume:

0.96

Market Cap:

$12.48B

Revenue:

$708.24M

Net Income/Loss:

$-188.30M

P/E Ratio:

-64.88

EPS:

-3.7392

Net Cash Flow:

$-70.99M

1W Performance:

+0.61%

1M Performance:

+4.42%

6M Performance:

+41.14%

1Y Performance:

+130.08%

1-Day Range:

$239.02

$251.25

1-Week Range:

$237.64

$251.25

52-Week Range:

$96.09

$260.19

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name

Axsome Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(212) 332-3241

Address

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Employee

925

Twitter

Next Earnings Date

2026-08-03

Latest SEC Filings

AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AXSM Axsome Therapeutics Inc	242.60	12.60B	708.24M	-188.30M	-70.99M	-3.7392
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-01-25	Initiated	B. Riley Securities	Buy
Sep-03-25	Resumed	Wells Fargo	Overweight
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-03-25	Initiated	Oppenheimer	Outperform
Apr-07-25	Initiated	Jefferies	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-31-24	Reiterated	Mizuho	Outperform
Sep-03-24	Initiated	Wells Fargo	Overweight
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy
Jul-22-24	Initiated	Needham	Buy
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-06-24	Initiated	UBS	Buy
Jan-25-24	Initiated	RBC Capital Mkts	Outperform
Dec-13-23	Initiated	Citigroup	Buy
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral
Jan-05-23	Initiated	Piper Sandler	Neutral
Nov-01-22	Initiated	Loop Capital	Buy
Sep-07-22	Resumed	Mizuho	Buy
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-10-21	Initiated	Berenberg	Buy
Jan-08-21	Initiated	Jefferies	Buy
Dec-16-20	Initiated	Mizuho	Buy
Sep-29-20	Initiated	BofA Securities	Underperform
Sep-10-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Reiterated	H.C. Wainwright	Buy
Apr-14-20	Initiated	Cowen	Outperform
Dec-30-19	Reiterated	H.C. Wainwright	Buy
Dec-17-19	Reiterated	H.C. Wainwright	Buy
Dec-16-19	Reiterated	Guggenheim	Buy
Oct-16-19	Initiated	Guggenheim	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-28-19	Initiated	SunTrust	Buy
May-23-19	Reiterated	H.C. Wainwright	Buy
Apr-08-19	Initiated	SVB Leerink	Outperform
Mar-15-19	Reiterated	H.C. Wainwright	Buy
Oct-03-16	Resumed	Brean Capital	Buy
Dec-15-15	Initiated	Cantor Fitzgerald	Buy
Dec-14-15	Initiated	Ladenburg Thalmann	Buy

View All

Axsome Therapeutics Inc Stock (AXSM) Latest News

Jul 01, 2026

Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares - Investing.com UK

Jul 01, 2026

Form 4 Axsome Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares By Investing.com - Investing.com Canada

Jul 01, 2026

Axsome Therapeutics (AXSM) CEO sells 49,666 exercised shares under 10b5-1 plan - Stock Titan

Jul 01, 2026

Form 144 Axsome Therapeutics For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

49,666-share sale notice for AXSM (NASDAQ: AXSM) via cashless exercise - Stock Titan

Jul 01, 2026

Why Axsome Stock Has Doubled In Nine Months - Yahoo! Finance Canada

Jul 01, 2026

Jun 30, 2026

AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits

Jun 30, 2026

Pictet Asset Management Holding SA Sells 20,080 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 30, 2026

Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 – DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com

Jun 30, 2026

Jun 29, 2026

Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Index - marketscreener.com

Jun 29, 2026

Axsome Therapeutics, Inc.(NasdaqGM: AXSM) added to Russell Midcap Growth Benchmark - marketscreener.com

Jun 29, 2026

Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026